{"url_path":"/sec/teva/8-k/2026-09-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","accession_number":"0001193125-26-389264","cik":"0000818686","ticker":"TEVA","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","primary_entity_key":"0000818686","primary_entity_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD"},"word_count":524,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events\n\nOn September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”), Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and together with Teva Finance II and Teva Finance III, the “Issuers”) and, the Company, as guarantor, entered into an underwriting agreement (the “Underwriting Agreement”) with BNP PARIBAS, BNP Paribas Securities Corp., Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE, J.P. Morgan SE and J.P. Morgan Securities LLC, as representatives for the underwriters named in Schedule 1 annexed thereto (the “Underwriters”), providing for the offer and sale by (a) Teva Finance II of (x) €1,000,000,000 aggregate principal amount of 4.250% Senior Notes due 2033 (the “2033 Euro Notes”) and (y) €500,000,000 aggregate principal amount of 4.625% Senior Notes due 2036 (the “2036 Euro Notes” and together with the 2033 Euro Notes, the “Euro Notes”), (b) Teva Finance III of (x) $1,000,000,000 aggregate principal amount of 5.500% Senior Notes due 2034 (the “2034 USD Notes”) and (y) $1,000,000,000 aggregate principal amount of 5.750% Senior Notes due 2037 (the “2037 USD Notes”), and (c) Teva Finance IV of $1,200,000,000 aggregate principal amount of 5.250% Senior Notes due 2032 (the “2032 USD Notes” and together with the 2034 USD Notes and 2037 USD Notes, the “USD Notes” and, together with the Euro Notes, the “Securities”). The sale of the Securities is expected to close on September 16, 2026.\n\nThe offering of the 2033 Euro Notes was priced at 98.756% of the €1,000,000,000 principal amount of the 2033 Euro Notes to be issued. The offering of the 2036 Euro Notes was priced at 98.327% of the €500,000,000 principal amount of the 2036 Euro Notes to be issued. The offering of the 2034 USD Notes was priced at 98.659% of the $1,000,000,000 principal amount of the 2034 USD Notes to be issued. The offering of the 2037 USD Notes was priced at 98.520% of the $1,000,000,000 principal amount of the 2037 USD Notes to be issued. The offering of the 2032 USD Notes was priced at 98.993% of the $1,200,000,000 principal amount of the 2032 USD Notes to be issued.\n\nThe offering of the Securities was registered under the Securities Act of 1933, as amended (the “Securities Act”), and is being made pursuant to the Company’s Registration Statement on Form S-3ASR (File No. 333-284770) and the prospectus included therein (the “Registration Statement”), filed by the Company with the Commission on February 7, 2025, and the prospectus supplement relating thereto, dated September 7, 2026, and filed with the Commission on September 8, 2026 pursuant to Rule 424(b) promulgated under the Securities Act. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and the Issuers. It also provides for customary indemnification by each of the Company, the Issuers and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.\n\nThe foregoing description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to the copy thereof which is filed herewith as Exhibit 1.1 and incorporated herein by reference."}